アスピリン抵抗性の疑いのある急性冠動脈症候群の後のアスピリン投与:ANDAMAN試験
Jean-Guillaume Dillinger1,2,3, Théo Pezel1,2, Laure Batias4
1Department of Cardiology, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Université Paris Cité, Inserm MASCOT-UMRS 942, 2 Rue Ambroise Paré, Paris 75010, France.
European heart journal
|August 30, 2025
まとめ
急性冠動脈症候群 (ACS) の後の糖尿病 (DM) または高リスクアスピリン抵抗性 (HRAR) の患者で,毎日2回アスピリンは重大な心血管不良事件 (MACE) を有意に低下させなかった. 血液出血の危険性は,1日1回と2日1回投与の間で類似していた.
科学分野:
- 心臓病科
- 薬理学について
- 臨床試験
背景:
- 糖尿病 (DM) またはアスピリン抵抗性後急性冠動脈症候群 (ACS) の高頻度
- 現在の抗血栓治療は,再発性心血管疾患の予防に限界を示しています.
研究 の 目的:
- ACS,DM,または高リスクアスピリン抵抗性 (HRAR) の患者で,アスピリンの二回投与が主要な心血管疾患 (MACE) を減少させるかどうかを調べる.
主な方法:
- ACSとDMまたはHRARの患者2484人を対象とした多センターランダム化試験です.
- 患者は,腸内コーティングされたアスピリン100 mgを1日1回,または100 mgを1日2回投与された.
- 主なアウトカム: MACE (死亡,心筋梗塞,脳卒中,緊急再血管化,ステント血栓症,または急性動脈血栓症)
主要な成果:
- 1日2回 (7. 7%) と1日1回 (8. 8%) のアスピリン群の間でMACEの有意な差は認められませんでした (HR 0. 90; 95% CI 0. 69- 1. 19; P = .42).
- 重度の出血率は2つの投与群で比較可能であった (1. 9% 対 2. 1%; HR 0. 88; 95% CI 0. 50 - 1.55).
- この研究では,DMの77. 2%,ST上昇性心筋梗塞の55. 5%が対象でした.
結論:
- アスピリンを1日2回投与すると,ADMまたはHRARのACS患者では,1日1回投与と比較してMACEが有意に低下することはありません.
- 投与レジミンの間で大きな出血の有意な違いは観察されなかった.
関連する概念動画
01:28Acute Coronary Syndrome IV: Interprofessional Care
26
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
26
01:26Acute Coronary Syndrome V: Nursing Management
37
Nursing Assessment:Nursing management of acute coronary syndrome (ACS) involves taking the patient's history, focusing on primary complaints such as chest pain, dyspnea, and excessive sweating (diaphoresis), as well as other symptoms like back or jaw pain, nausea, vomiting, palpitations, dizziness, and fatigue. The nurse also reviews the patient's history of cardiac events, risk factors such as hypertension, diabetes, smoking, family history, and current medications.In the objective assessment,...
37
01:30Acute Coronary Syndrome III: Diagnostic Studies
23
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
23
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
45
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
45
01:30Acute Coronary Syndrome I: Introduction
71
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
71
01:27Coronary Artery Disease V: Interprofessional Care
30
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
30